Cargando…

JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia

BACKGROUND: Mesenchymal stem/stromal cells (MSCs) derived from human embryonic stem cells (hESCs) are attractive for their hematopoietic-supporting or potential therapeutic effects. However, procedures for high-effective and scalable generation of MSCs from hESCs within 2 weeks are still unestablish...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yimeng, Hou, Huixing, Zhang, Leisheng, Zhao, Nianhuan, Li, Chengwen, Huo, Jiali, Liu, Ying, Zhang, Wenxia, Li, Zongjin, Liu, Dengke, Han, Zhibo, Zhang, Lei, Song, Baoquan, Chi, Ying, Han, Zhongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591900/
https://www.ncbi.nlm.nih.gov/pubmed/31234947
http://dx.doi.org/10.1186/s13287-019-1302-1
_version_ 1783429801813475328
author Wei, Yimeng
Hou, Huixing
Zhang, Leisheng
Zhao, Nianhuan
Li, Chengwen
Huo, Jiali
Liu, Ying
Zhang, Wenxia
Li, Zongjin
Liu, Dengke
Han, Zhibo
Zhang, Lei
Song, Baoquan
Chi, Ying
Han, Zhongchao
author_facet Wei, Yimeng
Hou, Huixing
Zhang, Leisheng
Zhao, Nianhuan
Li, Chengwen
Huo, Jiali
Liu, Ying
Zhang, Wenxia
Li, Zongjin
Liu, Dengke
Han, Zhibo
Zhang, Lei
Song, Baoquan
Chi, Ying
Han, Zhongchao
author_sort Wei, Yimeng
collection PubMed
description BACKGROUND: Mesenchymal stem/stromal cells (MSCs) derived from human embryonic stem cells (hESCs) are attractive for their hematopoietic-supporting or potential therapeutic effects. However, procedures for high-effective and scalable generation of MSCs from hESCs within 2 weeks are still unestablished, which also hinder the development and mechanism study of mesengenesis. METHODS: In this study, we aimed to establish a strategy for programming hESC differentiation into MSCs by practicing small-scale chemical compound screening. Then, we used flow cytometry, multi-lineage differentiation, and karyotype analyses to investigate the biological phenotypes of the derived hESC-MSCs. Also, to explore whether the derived cells had hematopoietic-supporting ability in vitro, we carried out the cobblestone formation and megakaryocytic differentiation experiments. To further evaluate the function of hESC-MSCs in vivo, we transplanted the cells into a mouse model with hind limb ischemia. RESULTS: By simultaneous treatments with a JAK/STAT antagonist and a DNA methylation inhibitor, the efficiency of generating hESCs into CD73(+) hESC-MPCs could reach 60% within 7 days. The derived cells further matured into hESC-MSCs, with comparable characteristics to those of adult MSCs in terms of surface markers, normal karyotype, and the potential for adipogenic, osteogenic, and chondrogenic differentiation. Functionally, hESC-MSCs had hematopoietic-supporting effects in vitro and could notably relieve symptoms of hind limb ischemia. CONCLUSIONS: In the study, we established a high-efficient procedure for large-scale generation of MSCs from hESCs, which would be of great help for genesis and mechanism studies of MSCs. Meanwhile, the derived cells provide an alternative for translational clinical research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-019-1302-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6591900
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65919002019-07-08 JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia Wei, Yimeng Hou, Huixing Zhang, Leisheng Zhao, Nianhuan Li, Chengwen Huo, Jiali Liu, Ying Zhang, Wenxia Li, Zongjin Liu, Dengke Han, Zhibo Zhang, Lei Song, Baoquan Chi, Ying Han, Zhongchao Stem Cell Res Ther Research BACKGROUND: Mesenchymal stem/stromal cells (MSCs) derived from human embryonic stem cells (hESCs) are attractive for their hematopoietic-supporting or potential therapeutic effects. However, procedures for high-effective and scalable generation of MSCs from hESCs within 2 weeks are still unestablished, which also hinder the development and mechanism study of mesengenesis. METHODS: In this study, we aimed to establish a strategy for programming hESC differentiation into MSCs by practicing small-scale chemical compound screening. Then, we used flow cytometry, multi-lineage differentiation, and karyotype analyses to investigate the biological phenotypes of the derived hESC-MSCs. Also, to explore whether the derived cells had hematopoietic-supporting ability in vitro, we carried out the cobblestone formation and megakaryocytic differentiation experiments. To further evaluate the function of hESC-MSCs in vivo, we transplanted the cells into a mouse model with hind limb ischemia. RESULTS: By simultaneous treatments with a JAK/STAT antagonist and a DNA methylation inhibitor, the efficiency of generating hESCs into CD73(+) hESC-MPCs could reach 60% within 7 days. The derived cells further matured into hESC-MSCs, with comparable characteristics to those of adult MSCs in terms of surface markers, normal karyotype, and the potential for adipogenic, osteogenic, and chondrogenic differentiation. Functionally, hESC-MSCs had hematopoietic-supporting effects in vitro and could notably relieve symptoms of hind limb ischemia. CONCLUSIONS: In the study, we established a high-efficient procedure for large-scale generation of MSCs from hESCs, which would be of great help for genesis and mechanism studies of MSCs. Meanwhile, the derived cells provide an alternative for translational clinical research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-019-1302-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-24 /pmc/articles/PMC6591900/ /pubmed/31234947 http://dx.doi.org/10.1186/s13287-019-1302-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wei, Yimeng
Hou, Huixing
Zhang, Leisheng
Zhao, Nianhuan
Li, Chengwen
Huo, Jiali
Liu, Ying
Zhang, Wenxia
Li, Zongjin
Liu, Dengke
Han, Zhibo
Zhang, Lei
Song, Baoquan
Chi, Ying
Han, Zhongchao
JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
title JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
title_full JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
title_fullStr JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
title_full_unstemmed JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
title_short JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
title_sort jnki- and dac-programmed mesenchymal stem/stromal cells from hescs facilitate hematopoiesis and alleviate hind limb ischemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591900/
https://www.ncbi.nlm.nih.gov/pubmed/31234947
http://dx.doi.org/10.1186/s13287-019-1302-1
work_keys_str_mv AT weiyimeng jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT houhuixing jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT zhangleisheng jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT zhaonianhuan jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT lichengwen jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT huojiali jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT liuying jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT zhangwenxia jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT lizongjin jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT liudengke jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT hanzhibo jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT zhanglei jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT songbaoquan jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT chiying jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia
AT hanzhongchao jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia